Takeda California has obtained an Import Drug License from China's Food and Drug Administration for Nesina, or alogliptin, as treatment for type 2 diabetes. The drug is an orally administered dipeptidyl peptidase-4 inhibitor developed to slow the inactivation of the incretin hormones glucose-dependent insulinotropic peptide and glucagonlike peptide-1.

Full Story:
BioSpectrum Asia

Related Summaries